Newly Developed Self-Assembling Antioxidants as Potential Therapeutics for the Cancers
Related Experiment Video
Updated: Nov 18, 2025

Production and Detection of Reactive Oxygen Species ROS in Cancers
Published on: November 21, 2011
Babita Shashni1, Yukio Nagasaki1,2,3
1Department of Materials Science, Graduate School of Pure and Applied Sciences, University of Tsukuba, Tennoudai 1-1-1, Tsukuba, Ibaraki 305-8573, Japan.
Abstract:
Elevated reactive oxygen species (ROS) have been implicated as significant for cancer survival by functioning as oncogene activators and secondary messengers. Hence, the attenuation of ROS-signaling pathways in cancer by antioxidants seems a suitable therapeutic regime for targeting cancers. Low molecular weight (LMW) antioxidants such as 2,2,6,6-tetramethylpyperidine-1-oxyl (TEMPO), although they are catalytically effective in vitro, exerts off-target effects in vivo due to their size, thus, limiting their clinical use. Here, we discuss the superior impacts of our TEMPO radical-conjugated self-assembling antioxidant nanoparticle (RNP) compared to the LMW counterpart in terms of pharmacokinetics, therapeutic effect, and adverse effects in various cancer models.
Insights
New antioxidant nanoparticles effectively target cancer by attenuating reactive oxygen species (ROS). These novel nanoparticles show improved pharmacokinetics and therapeutic effects compared to small molecule antioxidants, with fewer adverse effects in cancer models.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Therapeutics
Background:
- Elevated reactive oxygen species (ROS) are crucial for cancer cell survival, acting as oncogene activators and secondary messengers.
- Antioxidant-based therapies targeting ROS signaling pathways represent a promising strategy for cancer treatment.
- Low molecular weight (LMW) antioxidants like TEMPO have limitations in vivo due to off-target effects and size.
Purpose of the Study:
- To evaluate the efficacy of a novel TEMPO radical-conjugated self-assembling antioxidant nanoparticle (RNP) compared to LMW TEMPO.
- To assess the pharmacokinetic advantages, therapeutic effects, and safety profile of RNPs in preclinical cancer models.
Main Methods:
- Development of TEMPO radical-conjugated self-assembling antioxidant nanoparticles (RNPs).
- In vitro and in vivo evaluation of RNPs and LMW TEMPO in various cancer models.
- Assessment of pharmacokinetics, therapeutic efficacy, and adverse effects.
Main Results:
- RNPs demonstrated superior pharmacokinetics compared to LMW antioxidants.
- Enhanced therapeutic effects were observed with RNPs in preclinical cancer models.
- RNPs exhibited a more favorable safety profile with reduced adverse effects.
Conclusions:
- TEMPO-conjugated antioxidant nanoparticles offer a promising advancement in cancer therapy.
- RNPs overcome the limitations of LMW antioxidants, providing improved in vivo performance.
- This nanoparticle-based approach warrants further investigation for clinical translation in oncology.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Cancer Prevention
Some...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Radical Autoxidation

